Fecal microbiota transplant combined with immune therapy for lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the safety and efficacy of fecal microbiota transplantation (FMT) in patients with metastatic lung cancer receiving first-line (chemo-)immunotherapy. The approach involves using fecal samples from patients who have responded well to immunotherapy as donors for the transplant. Participants will receive FMT alongside their treatment regimen, with regular assessments of their microbiome composition and clinical outcomes. The study aims to enhance the effectiveness of immunotherapy by modulating the gut microbiome.

Why it matters

Who can join: the full rules

Patient (Recipient) Inclusion Criteria:

1. A histologically confirmed diagnosis of malignancy.
2. Patients over the age of 18.
3. Patients planning to be treated with chemotherapy, immune checkpoint inhibitors and/or targeted therapy.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
5. Able to provide written informed consent.

Patient (Recipient) Exclusion Criteria:

1. Severe or life-threatening food allergy (e.g. nuts, seafood)
2. Allergy or other contraindication to omeprazole, investigational medicinal product.
3. Treatment with pre- or probiotics in the four weeks prior to randomization.
4. Severe immunodeficiency:

   * Systemic chemotherapy \<30 days from baseline
   * Known neutropenia with absolute neutrophils \<1.0x109 cells/µL
   * Prolonged treatment with corticosteroids (equivalent to prednisone \>60mg daily for \>30 days) within 8 weeks of randomization
5. Swallowing disorder, oral-motor discoordination, inability to swallow capsules
6. Pregnant or breastfeeding or expecting to conceive or father children within the trial's projected duration, starting from the pre-screening or screening visit through to 120 days after the last dose of trial treatment.

Donor Inclusion Criteria:

1. A histologically confirmed diagnosis of malignancy.
2. Over the age of 18.
3. Treated with immune checkpoint inhibitors and with a full response.
4. Currently attending medical follow-ups

Donor Exclusion Criteria:

1. Has not consumed any antimicrobials within the past 3 months
2. No prior exposure to HIV or viral hepatitis or suffering from tuberculosis/latent tuberculosis
3. No risk factors for blood-borne viruses, including high-risk sexual behavior, use of illicit drugs, any tattoo/body piercing/needlestick injury/blood transfusion/acupuncture, all within the past 6 months
4. No signs or symptoms consistent with Coronavirus disease 19 (COVID-19) or a nose/throat and/or stool sample with detectable Coronavirus disease 2 (CoV-2)
5. Has not received a live attenuated vaccine within the past 6 months
6. No underlying gastrointestinal conditions/symptoms (e.g., history of IBD, irritable bowel syndrome (IBS), chronic diarrhea, chronic constipation, coeliac disease, bowel resection or bariatric surgery)
7. No acute diarrhea/gastrointestinal symptoms within the 2 weeks prior to donating
8. No family history of any significant gastrointestinal conditions (e.g., family history of inflammatory bowel disease (IBD) or colorectal cancer)
9. No history of atopy (e.g., asthma, eosinophilic disorders)
10. Does not suffer from any systemic autoimmune conditions
11. Does not start any new treatment regimens within 2 weeks of fecal collection
12. No neurological or psychiatric conditions or known risk for prion disease
13. No history of chronic pain syndromes, including chronic fatigue syndrome and fibromyalgia
14. No history of receiving growth hormone, insulin from cows or clotting factor concentrates
15. Has not received an experimental drug or vaccine within the past 6 months
16. No history of travel to tropical countries within the past 6 months

Where it's running

• Soroka Medical Center
  Beersheba, Israel Recruiting
• Rabin Medical Center
  Petah Tikva, Israel Not yet recruiting

Study contacts

• Principal investigator: Ismaell Massalha, MD — Soroka University Medical Center
• Study coordinator: Ismaell Massalha, M.D.
• Email: ismaell@post.bgu.ac.il
• Phone: +972526995934

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Does the time of day for PD-1/PD-L1 therapy affect response in NSCLC and HNSCC

  In people with advanced NSCLC or resectable head and neck cancer, this study tests whether receiving PD-1/PD-L1 therapy in the morning versus the afternoon changes treatment outcomes.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07630168

• Combination immunotherapy and radiotherapy in metastatic non-small cell lung cancer

  This trial will test whether adding immunotherapy to radiotherapy helps people with metastatic non-small cell lung cancer who have progressed on prior immunotherapy.

  Recruiting Phase 2 University of Chicago · Chicago, Illinois · NCT07603856

• Long-term survivors of metastatic lung cancer: health, quality of life, and needs

  This project will follow people who have lived at least three years with metastatic lung cancer and are no longer on cytotoxic chemotherapy to see what their health, quality of life, and social needs are.

  Recruiting at 31 sites Groupe Francais De Pneumo-Cancerologie · Aix-en-Provence and 45 other locations · NCT07243132

• Thinking and mood changes from ALK/ROS1 targeted drugs in metastatic lung cancer and a patient-research care pathway

  This project will look at thinking, memory, and mood changes in adults in France taking ALK/ROS1-targeted drugs for metastatic lung cancer to see how these effects affect daily life and to build a patient-research care pathway.

  Recruiting at 2 sites Hospices Civils de Lyon · Bron and 1 other locations · NCT06781905

• Evaluating BBO-10203 for advanced solid tumors

  This study is testing a new treatment called BBO-10203, alone and with another drug, to see if it can help people with advanced solid tumors, including certain types of breast cancer.

  Recruiting at 43 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Duarte, California and 43 other locations · NCT06625775

• Pulsed radiotherapy with immunotherapy for metastatic non-small cell lung cancer that stopped responding to prior treatment

  This phase 1 study tests whether giving adaptive pulsed radiotherapy together with PD-(L)1 inhibitors is safe and can help people with metastatic NSCLC whose cancer has progressed on immunotherapy.

  Recruiting Phase 1 Centre hospitalier de l'Université de Montréal (CHUM) · Montreal, Quebec · NCT06622174

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.